Background {#Sec1}
==========

Head and neck squamous cell carcinoma (HNSCC), which includes squamous cell carcinomas of the oral cavity, oropharynx, larynx, and hypopharynx, is the sixth most common cancer worldwide \[[@CR1], [@CR2]\]. Two main risk factors related to HNSCC are tobacco use and alcohol consumption \[[@CR3]\]. Recently, investigators have suggested that human papillomavirus (HPV) is a potential etiological factor of HNSCC in patients who do not smoke or drink alcohol, particularly in oropharynx squamous cell carcinoma (OPSCC) \[[@CR4], [@CR5]\]. The oncogenic proteins E6 and E7 of high-risk HPVs, such as HPV16 and HPV18, are considered to be associated with the carcinogenic process of OPSCC by inactivating the tumor suppressor genes p53 and Rb \[[@CR6], [@CR7]\]. However, the rate of detecting HPV in OSCC varies widely (0--100 %), and the role of HPV in oral carcinogenesis has long been controversial \[[@CR8]\].

HPV has been detected in not only cervical cancer but in cervical premalignant lesions as well, and the detection rate is known to increase with the severity of disease abnormality \[[@CR9]\]. Oral lesions and conditions associated with a risk of malignant transformation have been referred to as oral potentially malignant disorders (OPMD) and include oral leukoplakia (OLK), lichen planus, and erythroplakia \[[@CR10]\]. Recent studies have revealed a varying rate of detected HPV in OPMD \[[@CR8]\]. A better understanding of the true presence of HPV in OSCC and OPMD may thus contribute to further studies of these diseases.

Different techniques have been used to detect HPV, including in situ hybridization (ISH), Southern blot hybridization, dot blot hybridization, hybrid Capture 2 (hc2), conventional PCR, and real-time PCR \[[@CR11]\]. ISH, Southern blot and dot blot hybridization are time-consuming procedures that require relatively large amounts of purified DNA \[[@CR11]\]. Hc2 assay cannot genotype single HPV subtypes \[[@CR11]\]. Of these methods, studies using PCR techniques have reported a higher sensitivity for HPV detection \[[@CR12]\]. However, conventional PCR assays may have a lower sensitivity and specificity \[[@CR11]\]. Real-time PCR has a sensitivity of 92 % and a specificity of 97 % in detecting HPV and is able to genotype and quantitate HPV viral load \[[@CR13]\].

The aim of our study was to identify the detection rate of high-risk HPV types 16 and 18 in Chinese patients with OSCC and OPMD using real-time PCR and DNA sequencing.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

A total of 99 patients including 40 OSCC and 59 OPMD patients were enrolled from the Department of Oral Mucosal Diseases and the Department of Oral Maxillofacial Surgery at the Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine. Paired tissue and serum samples were collected from each patient. Tissue samples were immediately frozen at −80 °C after surgery. Serum was obtained from the supernatant of the collected whole blood and stored at −80 °C until processing. Histological diagnoses were made by one pathologist who was on duty and confirmed by a superior pathologist according to the World Health Organization criteria \[[@CR14], [@CR15]\]. This study was approved by an Independent Ethics Committee of Shanghai Ninth People\'s Hospital affiliated to Shanghai Jiao Tong University, School of Medicine (\#200703), and signed informed consent was obtained from each patient. The baseline characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}.Table 1The baseline characteristic of patientsIDDiagnosisAgeGenderSmokingAlcoholStage TNM^a^NotesTumor SiteTypeCXJ 1OSCC77MPastNeverreal-time PCRTongueCXJ 2OLK48FNeverSometimesreal-time PCRGingivaCXJ 3OLK36MCurrentCurrentreal-time PCRBuccalCXJ 4OSCC63MNeverPastreal-time PCRTongueCXJ 5OSCC54MCurrentPastreal-time PCRBuccalPapillaryCXJ 6OSCC60MCurrentCurrentreal-time PCRBuccalCXJ 7OSCC41MCurrentCurrentreal-time PCRTongueCXJ 8OSCC53MPastCurrentreal-time PCRBuccalCXJ 9OSCC41MCurrentCurrentreal-time PCRFloor of mouthCXJ 10OSCC69FNeverNeverT1M0N0real-time PCR & DNA sequencing (18 ZDNA)GingivaCXJ 11OSCC56MCurrentNeverreal-time PCR & DNA sequencing (16 SDNA)BuccalCXJ 12OSCC60FNeverNeverreal-time PCRGingivaCXJ 13OSCC58MCurrentSometimesreal-time PCRGingivaCXJ 14OSCC57FNeverNeverT2N0M0real-time PCRTongueCXJ 15OSCC55MSometimesSometimesreal-time PCRHard palatePapillaryCXJ 16OSCC75MNeverSometimesreal-time PCRBuccalCXJ 17OSCC66FNeverNeverT4N1M0real-time PCRBuccalCXJ 18OSCC63MNeverNeverT4N0M0real-time PCRBuccalCXJ 19OSCC43MCurrentCurrentT4N0M0real-time PCRGingivaCXJ 20OLK65MNeverSometimesreal-time PCRHard palateCXJ 21OLK56MCurrentSometimesreal-time PCRBuccalCXJ 22OLK78FNeverNeverreal-time PCRTongueCXJ 24OSCC59MCurrentCurrentreal-time PCRGingivaCXJ 25OSCC54FNeverNeverT1N0M0real-time PCRTongueCXJ 26OSCC72MNeverNeverT3N0M0real-time PCRTongueCXJ 27OSCC75FNeverNeverT1N0MOreal-time PCRTongueCXJ 28OSCC40MSometimesNeverreal-time PCRGingivaCXJ 30OLK56FNeverNeverreal-time PCR & DNA sequencing (16 SDNA)GingivaCXJ 31OLK60MCurrentNeverreal-time PCRGingivaCXJ 32OSCC44MCurrentCurrentreal-time PCRFloor of mouthCXJ 33OLK65MNeverNeverreal-time PCRBuccalCXJ 34OSCC81MNeverNeverreal-time PCRLipCXJ 35OLK63MNeverNeverreal-time PCRGingivaCXJ 36OSCC58FNeverNeverreal-time PCRTongueCXJ 37OLK72MNeverNeverreal-time PCRGingivaCXJ 38OLK75MNeverNeverreal-time PCRBuccalCXJ 39OLK73MPastNeverreal-time PCRTongueCXJ 40OSCC60FNeverNeverreal-time PCRBuccalCXJ 41OLK36MNeverSometimesreal-time PCRGingivaCXJ 42OLK57FNeverNeverreal-time PCRBuccalCXJ 43OLK51MPastPastreal-time PCRTongueVerrucousCXJ 44OLK54MPastNeverreal-time PCRGingivaCXJ 45OLK56MNeverSometimesreal-time PCRTongueCXJ 46OLK66FCurrentNeverreal-time PCRGingivaCXJ 47OLK62MNeverPastreal-time PCRTongueCXJ 48OLK50FNeverNeverreal-time PCRGingivaCXJ 49OSCC63MCurrentSometimesreal-time PCRBuccalCXJ 50OLK53FNeverNeverreal-time PCRTongueCXJ 51OLK54MCurrentPastreal-time PCRSoft palateVerrucousCXJ 52OLK30MCurrentSometimesreal-time PCRTongueCXJ 53OLK62MCurrentSometimesreal-time PCRSoft palateCXJ 54OLK64FNeverNeverreal-time PCRBuccalCXJ 55OSCC70MPastCurrentreal-time PCRBuccalCXJ 56OLK50FNeverNeverreal-time PCR & DNA sequencing (16 SDNA, 18 SDNA)TongueCXJ 57OSCC73FNeverNeverreal-time PCR & DNA sequencing (18 SDNA)BuccalCXJ 58OLK59FNeverNeverreal-time PCRTongueCXJ 59OLK62FNeverNeverreal-time PCRGingivaCXJ 60OLK57FCurrentNeverreal-time PCRTongueCXJ 61OLK51MCurrentNeverreal-time PCRTongueCXJ 62OLK50FNeverNeverreal-time PCRTongueCXJ 63OSCC67MCurrentNeverreal-time PCRBuccalCXJ 64OLK64MNeverNeverreal-time PCRTongueCXJ 65OLK45FNeverNeverreal-time PCRGingivaCXJ 66OLK60MNeverNeverreal-time PCRBuccalCXJ 67OLK66FNeverNeverreal-time PCRTongueCXJ 68OSCC38MCurrentSometimesreal-time PCRTongueCXJ 69OSCC61MPastPastreal-time PCR & DNA sequencing (18 ZDNA)BuccalCXJ 70OLK52FNeverNeverreal-time PCRTongueCXJ 71OLK35MPastSometimesreal-time PCRBuccalCXJ 72OLK58FNeverNeverreal-time PCRBuccalCXJ 73OLK + EK37MPastPastreal-time PCRTongueCXJ 74OSCC34MCurrentCurrentreal-time PCRTongueCXJ 75OSCC53MCurrentCurrentreal-time PCRTongueCXJ 76OLK71FNeverNeverreal-time PCRTongueCXJ 77OSCC58FNeverNeverreal-time PCRTongueCXJ 78OLK58FNeverNeverreal-time PCRBuccalCXJ 79OLK + EK37FNeverNeverreal-time PCRTongueCXJ 80OLK53MPastCurrentreal-time PCRTongueCXJ 81OSCC58MPastSometimesreal-time PCRTongueCXJ 82OLK55FNeverNeverreal-time PCRTongueCXJ 83OLK53MCurrentCurrentreal-time PCRTongueCXJ 84OLK53MCurrentCurrentreal-time PCRHard palateVerrucousCXJ 85OLK54FNANAreal-time PCRTongueCXJ 86OLK54FNeverNeverreal-time PCRTongueCXJ 87OLK63MSometimesCurrentreal-time PCRTongueCXJ 88OLK72MNeverCurrentreal-time PCRGingivaCXJ 89OLK79FNeverNeverreal-time PCRBuccalCXJ 90OLK55MPastSometimesreal-time PCRTongueCXJ 91EK45FNeverNeverreal-time PCRBuccalCXJ 94OLP54FNeverNeverreal-time PCRBuccalCXJ 95OLP54FNeverNeverreal-time PCR & DNA sequencing (18 SDNA)BuccalCXJ 96OLP29MCurrentSometimesreal-time PCRBuccalCXJ 97OLP40FNeverNeverreal-time PCRBuccalCXJ 98OLP58FNeverNeverreal-time PCRBuccalCXJ 99OLP28MCurrentNeverreal-time PCRBuccalCXJ 100OSCC28MCurrentCurrentreal-time PCR & DNA sequencing (18 ZDNA)BuccalCXJ 101OSCC62FNeverNeverreal-time PCRGingivaCXJ 102OSCC68MNeverNeverreal-time PCRTongueCXJ 103OSCC59MNeverNeverreal-time PCR & DNA sequencing (18 ZDNA)Buccal*OSCC* oral squamous cell carcinoma, *OLK* oral leukoplakia, *OLP* oral lichen planus, *EK* oral erythroplakia, *ZDNA* tissue DNA, *SDNA* serum DNA, *NA* data not available^a^Union for International Cancer Control; T, tumor size; N, lymph node; M, Metastasis

Cell culture {#Sec4}
------------

The CAL27 cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MA, USA) and was grown in Dulbecco's Modified Eagle Medium (HyClone, Logan, UT, USA) containing 10 % fetal bovine serum (FBS) and 1 % penicillin-streptomycin solution at 37 °C in 5 % CO~2~.

DNA extraction {#Sec5}
--------------

Twenty 20-μm sections were cut from the frozen tissue samples, and DNA was extracted using the QIAamp DNA Micro Kit (Qiagen, Düsseldorf, Germany). Serum DNA extraction was performed using the QIAamp DNA Blood Mini Kit (Qiagen, Düsseldorf, Germany). CAL27 cells were detached by trypsinization and extracted DNA with QIAamp DNA Mini Kit (Qiagen, Düsseldorf, Germany). The plasmid pB-actin 16 E6 and pB-actin 18 E6 were bought from Addgene (Cambridge, MA, USA). Plasmid DNA was extracted using the QIAfilter MidiKit (Qiagen, Düsseldorf, Germany). Purified plasmid DNA were sequenced and blasted with HPV16 E6 (NC_001526.2) and HPV18 E6 (NC_001357.1) NCBI reference sequence. The extracted DNA was stored at −80 °C until further use.

Real-time PCR and sequencing {#Sec6}
----------------------------

Real-time PCR was performed by LightCycler 480 SYBR Green I Master (Roche, Basel, Switzerland) together with 0.5 μmol/L of each primer and 50 ng DNA in a 10 μl reaction were utilized. Positive controls were performed, which including HPV plasmid DNA, HPV containing cell line DNA and small amount of plasmids added to clinical sample DNA (Fig. [1](#Fig1){ref-type="fig"}). Negative controls were also performed, which including pure water, pure water instead of 2 × master mixture, pure water instead of positive control DNA (Fig. [1](#Fig1){ref-type="fig"}). A standard curve was developed for both HPV16 E6 (Fig. [2a](#Fig2){ref-type="fig"}) and HPV18 E6 (Fig. [2b](#Fig2){ref-type="fig"}) using a series of 10-fold diluted plasmid DNA 1 ng to 0.1 pg. The quantitated data was normalized by beta-actin (ACTB) using CAL27 genomic DNA. The reaction was performed by initiation at 95 °C for 5 min followed by 35 cycles of 95 °C for 10 s, 60 °C for 20 s and 72 °C for 10 s. Each sample was performed in triplicate. A sample was considered positive for HPV infection if two or three wells of the triplicate showed an amplifying curve. It was under suspicion if the amplifying curve was detected later than the 30^th^ cycle of the reaction or had a deformed shape. The suspicious samples of HPV16 E6 or HPV18 E6 were then sequenced to rule out false positives. All primers are shown in Table [2](#Tab2){ref-type="table"}.Fig. 1Positive and negative controls for HPV16 and HPV 18 with real-time PCR. **a** Positive and negative controls for HPV16; **b** Positive and negative controls for HPV18. Standard curve 1--5, 10-fold diluted HPV16 E6 or HPV18 E6 plasmid DNA ranging from 1 ng/well to 0.1 pg/well. Positive control 1, cilnical DNA sample added with 0.1 pg HPV16 E6 or HPV18 E6 DNA. Positive control 2, 50 ng Hela cell DNA. Negative control 1, pure water. Negative control 2, pure water instead of 2 × master mixture. Negative control 3, pure water instead of positive control DNAFig. 2Standard curves for HPV16 and HPV 18 E6. **a** Standard curves for 10-fold diluted HPV16 E6 plasmid DNA ranging from 0.1 ng/well to 0.1 pg/well; **b** Standard curves for 10-fold diluted HPV18 E6 plasmid DNA ranging from 1 ng/well to 0.1 pg/wellTable 2Sequence of HPV16 and HPV18 E6 primers and ACTB primers used for real-time PCRNameSequenceHPV16 E6-FGTCATATACCTCACGTCGCAGHPV16 E6-RAGCGACCCAGAAAGTTACCACHPV18 E6-FGTTTCTCTGCGTCGTTGGAGHPV18 E6-RGGTGCCAGAAACCGTTGAATACTB-FTCCCTCTCAGGCATGGAGTCACTB-RAATGCCAGGGTACATGGTGG

Results {#Sec7}
=======

Real-time PCR was conducted to detect HPV16 E6 and HPV18 E6 DNA. We found that zero of the 99 tissue samples (0 %) showed a standard amplifying curve for HPV 16 E6, but a few samples showed late or deformed amplifying curves in one of the triplicates, which were clearly not considered to be positive (Fig. [3a](#Fig3){ref-type="fig"}). Thirty-nine of 40 OSCC and 57 of 59 OPMD serum samples did not show a standard amplifying curve for HPV 16 E6 using real-time PCR, but 1 OSCC and 2 OPMD serum samples had a late or deformed amplifying curve in two or three wells of the triplicate that was suspicious (Fig. [3b](#Fig3){ref-type="fig"}). In addition, 36 of 40 OSCC and all 59 OPMD tissue samples were negative for the standard amplifying curve of HPV 18 E6, but 4 OSCC tissue samples presented a late and deformed amplifying curve in two or three wells of the triplicate (Fig. [3c](#Fig3){ref-type="fig"}). Thirty-nine of 40 OSCC and 57 of 59 OPMD serum samples were negative for the standard amplifying curve of HPV 18 E6, but 1 OSCC and 2 OPMD serum samples had late and deformed amplifying curves in two or three wells of the triplicate (Fig. [3d](#Fig3){ref-type="fig"}). DNA sequence analysis was then performed on the suspicious samples, which found that all of the samples sequenced were negative for HPV16 and HPV18. Overall, 3 of 198 (1.52 %) and 7 of 198 (3.54 %) samples were false-positive for HPV16 E6 and HPV18 E6, respectively, using real-time PCR. Overall, none of the OSCC or OPMD cases were positive for HPV 16 or18 in our study.Fig. 3Amplification curves for HPV16 and HPV 18 with real-time PCR. **a** Detection of HPV16 E6 in tissue samples; **b** Detection of HPV16 E6 in serum samples; **c** Detection of HPV18 E6 in tissue samples; **d** Detection of HPV18 E6 in serum samples

Discussion {#Sec8}
==========

In the past few decades, there has been speculation worldwide about the role of HPV in the pathogenesis of HNSCC. The most commonly detected HPV, HPV16, accounts for 90 % of the HPV DNA-positive cases in HNSCC, followed by HPV18 and other high-risk subtypes \[[@CR16]\]. However, the detection rate of HPV in OSCC and OPMD varies widely and remains controversial \[[@CR8], [@CR17]\]. This variation may due to differences in the types of sample, detection methods or geographic locations \[[@CR8], [@CR18]\]. Therefore, confirming the HPV infection rate in OSCC and OPMD cases may contribute to the study of carcinogenesis in the oral cavity \[[@CR19], [@CR20]\]. In this study, we used real-time PCR to detect HPV16 and HPV18 in paired tissue and serum samples of Chinese OSCC and OPMD patients \[[@CR21]\]. We conducted complementary analyses to verify the results of the real-time PCR with DNA sequencing. We found that none of the patients with OSCC or OPMD demonstrated existence of high-risk HPV16 or HPV18. The absence of HPV DNA in our sample implies that HPV infection may not be common in Chinese patients with OSCC and OPMD.

A critical step in malignant transformation is the integration of high-risk HPV DNA into the human cellular genome, followed by the expression of the oncoproteins E6 and E7, which promote tumor progression \[[@CR21]\]. In a previous study, although the reported detection rate of high-risk HPV DNA in OSCC was 6.6 %, HPV mRNA was only detected in 5.9 % \[[@CR22]\]. These findings indicated that the mRNA or oncoproteins of HPV E6 and E7 were less commonly found than the DNA, as the presence of HPV in the genome differed from the HPV-related etiology \[[@CR23], [@CR24]\]. The gold standard to identify the presence of HPV was therefore suggested to be detecting HPV DNA \[[@CR25]\].

Yadav et al. showed that the HPV DNA detection limit for conventional PCR was 200 copies, whereas for real-time PCR, which has a higher sensitivity, detecting HPV DNA required only 1 copy \[[@CR26]\]. Lingen et al. detected high-risk HPV DNA in 9.8 % of OSCC cases using consensus primer PCR, but the positive rate was 6.6 % using real-time PCR \[[@CR22]\]. Scapoli et al. found the detection rate of HPV16 to be 2 % in OSCC with real-time PCR \[[@CR27]\]. Real-time PCR shows a higher sensitivity and specificity than conventional PCR assays \[[@CR12], [@CR22], [@CR26]\]. In the current study, we utilized real-time PCR and found that 3 of 198 samples showed late and deformed amplifying curves of HPV 16 E6 and 7 of 198 samples had late and deformed amplifying curves of HPV 18 E6. To rule out false positives, we performed subsequent sequencing and found that the rate of false positives using real-time PCR to detect HPV16 E6 and HPV18 E6 DNA was 1.52 and 3.54 %, respectively. Ha et al. found a 2 % false-positive rate for real-time PCR using the minimum criteria of HPV DNA copy number, which was similar to our results \[[@CR12]\].

The population has also been considered to be another factor affecting rate diversification. Several countries have revealed a zero detection rate of OSCC, including India \[[@CR28]--[@CR30]\], Brazil \[[@CR31]\], Japan \[[@CR32]\] and Mozambique \[[@CR33]\]. Other reported detection rates have been 1.54 % in Thailand \[[@CR34]\], 6.6 % in America \[[@CR22]\], 5 % in Mexico \[[@CR35]\], 39.4 % in Spain \[[@CR36]\] and 66.7 % in Sudan \[[@CR37]\]. Studies performed in China have yielded varied results using conventional PCR assays, ranging from 2.2 to 74 % \[[@CR38]--[@CR42]\]. However, real-time PCR data for OSCC has not been reported in China. Our study revealed a zero detection rate of HPV16 and 18 in OSCC by combining real-time PCR and DNA sequencing, which was a reliable method and provided further understanding of HPV infection in Chinese patients.

HPV infection has been identified in cancers of the cervix \[[@CR43]\], vulva \[[@CR44]\], vagina \[[@CR44]\], anus \[[@CR44]\], penis \[[@CR45]\] and oropharynx \[[@CR46]\]. It is widely accepted that OPSCCs, especially tonsillar cancers, are frequently associated with HPV infection \[[@CR17]\]. The recent reported prevalence of HPV in OPSCC was approximately 60-70 % \[[@CR47]\], but the corresponding rate was substantially lower and significantly varied in OSCC \[[@CR8], [@CR17]\]. HPV prevalence in OPSCC has been suggested to be an independent prognostic factor \[[@CR47]\]. HPV-positive OPSCC has been shown to be distinct from HPV-negative OPSCC with regard to prognosis \[[@CR48]--[@CR50]\]. However, there have been no direct correlations between HPV infection and oral carcinogenesis \[[@CR23], [@CR27], [@CR51]\].

HPV has been detected not only in cancer but also in premalignant lesions, such as in lesions of the cervix and breast \[[@CR9], [@CR52], [@CR53]\]. In contrast, there was a lack of HPV in premalignant lesions of the colon \[[@CR54]--[@CR56]\]. Interestingly, Ha et al. demonstrated a low prevalence (1.1 %) of HPV16 in OPMD \[[@CR12]\]. Similarly, we detected no presence of HPV 16 and 18 in Chinese patients with OPMD.

Conclusion {#Sec9}
==========

Overall, we demonstrated a prevalence rate of 0 % of HPV 16 and 18 in Chinese patients with OSCC and OPMD. Our data suggests that high-risk HPV16 and HPV18 infection may not be common in Chinese patients with OSCC and OPMD. Combining real-time PCR and DNA sequence for HPV DNA detection is an effective strategy to eliminate false positives.
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